myelodysplastic syndromes (MDS) is a $3.5b market and Syntara only need to contribute 700k, more importantly it go straight into Phase 2 later this year.
This is substantially more commercialized focus and less time consuming than the previous myelofibrosis trails.
Not sure how long it'll take before the market realize this.
Ann: SNT to Trial New Cancer Indication Following MRFF Grant, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
-0.001(4.17%) |
Mkt cap ! $27.46M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.2¢ | $36.31K | 1.599M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 793867 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 242619 | 3 |
View Market Depth
| Last trade - 15.46pm 25/06/2024 (20 minute delay) ? |
| SNT (ASX) Chart |